↓ Skip to main content

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.

Overview of attention for article published in Clinical Cancer Research, December 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news
2 news outlets
twitter
8 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
41 Mendeley